Contemporary and Emerging Approaches to Bladder-Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer.

Bladder-preserving trimodality therapy (TMT), consisting of trans-urethral bladder tumor resection followed by concurrent chemoradiotherapy, is an established standard of care for patients with muscle-invasive bladder cancer. For appropriately selected patients, TMT offers oncologic outcomes comparable to radical cystectomy while preserving the patient's native bladder. Optimal TMT outcomes require careful patient selection, which is currently based on clinical and pathologic factors. The role of immune checkpoint blockade (ICB) in TMT is currently being investigated in several on-going clinical trials. In the future, molecular features associated with response to TMT or ICB may further improve patient selection and guide post-treatment surveillance.
Competing Interests: Disclosure D.J. Konieczkowski: none. J.A. Efstathiou: consulting (Blue Earth Diagnostics, Boston Scientific, AstraZeneca), Advisory Board (Roivant); honoraria (UpToDate). K.W. Mouw: research funding (Pfizer); consulting (EMD Serono/Pfizer); honoraria (UpToDate, OncLive).
(Copyright © 2021 Elsevier Inc. All rights reserved.)